Key Takeaways
- Resilient margins in a brutal cycle: EBITDA margin rose 70 bps YoY to 14.5% despite severe destocking and price competition in Crop Protection, as cost optimization and a pharma recovery kicked in.
- The recovery is a second-half FY25 story: Management expects demand normalization only toward the end of H1 FY25, with pharma margins returning to historical levels and crop improving from Q3 FY25 onward.
- Animal Health is the big bet, but patience required: A new multipurpose plant is commissioned, validation takes 12–14 months, and the INR 200–300 crore revenue potential is 3–4 years out.
- CDMO mix shift is the margin lever: The pipeline is moving up the value chain from intermediates to patented-side APIs, where RM passthrough masks structurally higher percentage margins.
- What to watch next quarter: Whether the two large new facilities begin contributing revenue, any early signs of crop demand stabilization, and the pace of CDMO project ramp-ups in H2.
Pharma: Recovery Taking Shape
- API business gaining traction: Sequential and YoY growth driven by market share gains in legacy products and regulatory filings bearing fruit across Japan, Latin America and the Middle East.
- CDMO still under pressure: Destocking continues to weigh on the CDMO business, though a healthy project pipeline is maintained and 2 Phase III opportunities are progressing toward commercialization.
- Margin recovery path: Raw material prices have softened and stabilized, and cost-effectiveness measures are flowing through; operating profit revived 56% sequentially. Management expects pharma margins to return to historical levels in H2 FY25.
- API pipeline depth: 8 to 10 products under development, on track to launch 3 to 4 products every year, which supports the medium-term growth narrative.
Sameer Hiremath: "First, I think operating leverage itself will improve our margins from where we are today. Currently, the plants are not fully utilized because of the global macro crisis taking place. Once we get that back into steady state, then already operating leverage will improve our margins and the new products that come in to fold in the next 3 to 4 years, we'll have a better margin profile. The blended margin will be higher than historical margins on a stepwise basis, they're moving towards that, yes."
Crop Protection: Waiting for the Cycle
- Destocking and price competition persist: The global crop protection industry remains turbulent, with intense price competition and delayed recovery amplified by higher interest rates.
- Sequential improvement despite headwinds: Revenue grew sequentially on the back of improved CDMO segment performance, and cost improvement initiatives helped maintain the margin profile.
- Own-products demand still weak: Destocking continues to hit demand for Hikal's own crop protection products across the globe.
- Recovery timeline is uncertain: Management estimates crop conditions start improving from Q3 FY25, but acknowledges "Q3 or Q4 of the year is anyone's guess."
Sameer Hiremath: "Crop is undergoing massive stress as we know. It is going to be Q3 or Q4 of the year that anyone's guess."
Animal Health: The Long-Gestation Growth Engine
- New plant commissioned: A multipurpose Animal Health plant at Panoli, Gujarat was commissioned toward the end of Q3 FY24, marking a significant milestone in a multi-year build.
- Validation runway: The plant will undergo validation for the next 12 to 14 months before commercialization, meaning an idle period while customer registrations are secured.
- Revenue potential: Management sees INR 200–300 crores of revenue potential from this asset in 3–4 years, with margins initially creeping up to company level before operating leverage drives expansion.
- Infrastructure-heavy capex: The large infrastructure investment required for this plant weighs on blended asset turns (1.1x), but management notes the next phase of capex will be more revenue-generating in nature.
Anish Swadi: "So in the initial stages, the margin will creep up to where the company margin is once it stabilizes, right?"
CDMO: The Margin Story Beneath the Surface
- Moving up the value chain: Hikal is transitioning from intermediate supplier to API opportunities on the patented side, with customers entrusting IP and technology, a signal of deepening relationships.
- Margin structure advantage: CDMO margins are percentage-based with raw material passthrough, but because RM is a small part of total cost on-patent, realized margins are significantly higher than current company-level margins.
- Pipeline building: Currently 3–4 CDMO products are under development, expected to ramp up in the second half of FY25, which should start shifting the blended margin profile.
- Long-term mix ambition: Management intends to grow the CDMO share significantly over the next 3–4 years, though it declined to quantify a target range when pressed.
Sameer Hiremath: "It's a fixed margin and RM is just passthrough, but the margins are significantly higher than the current company margins here on the CDMO. Because these are... Sorry, it is percentage, but the RM is passthrough. But RM is a small part of the total cost because it's on patent. So margins are pretty high."
Capex & Capacity: Front-Loaded for Growth
- Two large facilities nearing operation: One large multipurpose plant is under commissioning and expected to finish this quarter or next; a second multipurpose facility at Panoli for Crop Protection is completed and stabilizing.
- CWIP to revenue conversion: Approximately INR 500 crores of capital work-in-progress will become operational definitely by Q2, with the split tilted largely toward Crop Protection.
- Cost front-loading: Other expenses are rising because these two big facilities are incurring costs ahead of revenue contribution; management expects this to neutralize as new business ramps up.
- Capex trajectory: INR 200 crores targeted for FY24 with INR 170 crores already spent; typical annual capex of INR 150–200 crores expected to continue into FY25.
- Utilization headroom: Pharma plants are at 75–80% utilization, while crop plants are lower due to destocking, leaving significant operating leverage available when demand returns.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Demand normalization | Recovery expected toward end of H1 FY25 | End of H1 FY25 |
| Pharma margin recovery | API and CDMO margins back to historical levels | H2 FY25 |
| Crop Protection recovery | Improvement from Q3 FY25 onward, per current estimate | Q3 FY25 onward |
| CDMO product ramp-up | 3–4 products under development to begin contributing | H2 FY25 |
| CWIP operational | INR 500 crores CWIP to become operational | By Q2 FY25 |
| Animal Health revenue | INR 200–300 crores potential from new plant | 3–4 years out |
| Long-term revenue | INR 3,000–3,200 crores target | FY27–28 |
| Capex spend (FY24) | INR 200 crores target, INR 170 crores done | Balance in Q4 FY24 |
| API product launches | 3–4 products per year from 8–10 product pipeline | Annual cadence |
Key Metrics
| Metric | Q3 FY24 |
|---|---|
| Revenue | ₹448 cr |
| EBITDA | ₹65 cr |
| EBITDA margin | 14.5%, up 70 bps YoY |
| 9M FY24 revenue | ₹1,271 cr |
| 9M FY24 EBITDA | ₹173 cr |
| 9M FY24 EBITDA margin | 13.6%, up 230 bps YoY |
| Interim dividend | 30% for FY24 |
| Pharma segment revenue | ₹267 cr |
| Pharma segment EBIT margin | 6.9% |
| Pharma segment 9M FY24 revenue | ₹763 cr |
| Pharma segment 9M FY24 EBIT margin | 5.2% |
| Pharma operating profit sequential growth | 56% QoQ |
| Crop Protection segment revenue | ₹180 cr |
| Crop Protection segment EBIT margin | 12.1% |
| Crop Protection segment 9M FY24 revenue | ₹508 cr |
| Crop Protection segment 9M FY24 EBIT margin | 11.9% |
| CDMO share of total revenue | Over 50% |
| Company volume change | Down 9% YoY, down 6% QoQ |
| Crop Protection volume change | Down 10% QoQ |
| Pharma volume change | Down 2% QoQ |
| Pharma plant utilization | 75% to 80% |
| Capex incurred in 9M FY24 | ~₹170 cr of the ₹200 cr annual target |
| Typical annual capex | ₹150 cr to ₹200 cr |
| CWIP | ~₹500 cr |
| Animal Health potential revenue in 3–4 years | ₹200 cr to ₹300-odd cr |
| FY23 revenue | Crossed ₹2,000 cr (per an analyst's math) |